From an InterestingEngineering.com online article:
“We are extremely proud of what we have accomplished, from the ability to 3D bioprint human cardiac tissue last summer to a mini heart with full structure now. These milestones are a testament to the hard work of our team and the proprietary process we have developed that enables this type of scientific achievement,” said Birla in a press release. “We believe we are at the forefront of whole heart bioengineering, a field that has matured quickly over the last year, and well-positioned to continue our rapid scientific advancement.”
BIOLIFE4D, the biotech company based out of Chicago, announced it has successfully demonstrated the ability to 3D bioprint a mini human heart, a big step in someday printing out a full-sized human heart that can be used for a transplant.
Researchers say they’ve successfully plunged human livers to subzero temperatures and then warmed them back up.
The “supercooled” organs were still in good shape after 27 hours, adding nearly a day to how long livers can last outside the body.
The supply of donor hearts, kidneys, and livers from accident victims is sharply limited. In the US, a nationwide system of registries and transplant centers coordinates to move them around by air in coolers for what are invariably emergency surgeries.
The research is part of a wider effort to learn how to keep organs operational outside the body for longer periods of time.
From a Washington University School of Medicine news release:
A blood test to detect the brain changes of early Alzheimer’s disease has moved one step closer to reality. Researchers from Washington University School of Medicine in St. Louis report that they can measure levels of the Alzheimer’s protein amyloid beta in the blood and use such levels to predict whether the protein has accumulated in the brain. The findings represent a key step toward a blood test to diagnose people on track to develop the devastating disease before symptoms arise.
Up to two decades before people develop the characteristic memory loss and confusion of Alzheimer’s disease, damaging clumps of protein start to build up in their brains. Now, a blood test to detect such early brain changes has moved one step closer to clinical use.
Researchers from Washington University School of Medicine in St. Louis report that they can measure levels of the Alzheimer’s protein amyloid beta in the blood and use such levels to predict whether the protein has accumulated in the brain. When blood amyloid levels are combined with two other major Alzheimer’s risk factors – age and the presence of the genetic variant APOE4 – people with early Alzheimer’s brain changes can be identified with 94% accuracy, the study found.